Antifungals

SCYNEXIS Announces Two Oral Presentations on Pooled Data from the BREXAFEMME (Ibrexafungerp tablets) Phase 3 VANISH Program Demonstrating Consistent Efficacy in the Treatment for Vaginal Yeast Infections at the IDSOG 2021 Virtual Annual Meeting

Retrieved on: 
Thursday, July 29, 2021

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • The New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021.

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

Retrieved on: 
Monday, July 12, 2021

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains.

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
Wednesday, June 30, 2021

Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.

Key Points: 
  • Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections incriticallyilland cancer patients.
  • Rezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis.
  • The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

Retrieved on: 
Wednesday, June 23, 2021

BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC), or vaginal yeast infections.

Key Points: 
  • BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC), or vaginal yeast infections.
  • Dr. Taglietti has served as Chief Executive Officer of SCYNEXIS since April 2015 and became President of the Company in September 2015.
  • Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: the BREXAFEMME launch update and the second half 2021 commercial plan for BREXAFEMME.
  • SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cidara to Present at Mycology 2021 Conference

Retrieved on: 
Wednesday, June 2, 2021

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidaras novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.

Key Points: 
  • SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidaras novel, once-weekly echinocandin, for the treatment and prevention of invasive fungal disease at the Mycology 2021 Conference, which takes place online from June 11-12, 2021.
  • Presentation details are as follows:
    Presenter: Dr. Varun Mehra, Department of Hematology & Stem Cell Transplantation, Kings College Hospital, London
    To register and view the full schedule, visit Mycology 2021 Conferences website here .
  • A copy of the presentation can be accessed in the Publications section of the Cidara website once the presentation concludes.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.

US Onychomycosis Market Size, Trends & Forecasts Report 2021-2025: Distal Subungual, White Superficial, Proximal Subungual, Endonyx and Candidal Onychomycosis - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021

3.1 Global Nail Care Market: An Analysis

Key Points: 
  • 3.1 Global Nail Care Market: An Analysis
    4.1 The US Nail Care Market: An Analysis
    4.2 The US Onychomycosis Market: An Analysis
    4.3 The US Onychomycosis Market: Type of Treatment Analysis
    4.4 The US Onychomycosis Market: Drug Availability Analysis
    4.5 The US Onychomycosis Market: Prescription Drugs Analysis
    4.6 The US Onychomycosis Market: OTC Drugs Analysis
    5.1 Competition in Onychomycosis Prescription Market: An Overview

TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India

Retrieved on: 
Wednesday, May 26, 2021

Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.

Key Points: 
  • Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.
  • With the recent surge of infections in India, AmphoTLC will address the countrys acute liposomal amphotericin B shortage.
  • The approval of AmphoTLC in India follows the conduct of complete due diligence by regulators in India based on the numerous years of development TLC has dedicated as well as its quality performance in the developed markets.
  • TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology and infectious diseases.

TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India

Retrieved on: 
Tuesday, May 25, 2021

AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.

Key Points: 
  • AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis.
  • The increasing number of CAM cases has resulted in unprecedently high demand for liposomal amphotericin B, the key drug to treat mucormycosis, causing an acute shortage of the drug.
  • Exploitation by sellers on the black market, who are marking up the price of liposomal amphotericin B by three times, is further exacerbating the situation.
  • The registration allows for immediate importation of AmphoTLC as per approved usage and indication of liposomal amphotericin B in India, which includes mucormycosis, to help alleviate the urgent need for the drug.

Global Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Analysis

Retrieved on: 
Thursday, March 18, 2021

DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 18, 2021 /PRNewswire/ -- The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the global systemic aspergillosis and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.

Insights on the Systemic Aspergillosis and Systemic Candidiasis Global Market to 2027 - by Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, March 15, 2021

The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Aspergillosis and Systemic Candidiasis Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Type, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report provides trends prevailing in the global systemic aspergillosis and systemic candidiasis market, and the drivers and hindrances pertaining to the market growth.
  • Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others.
  • Rise in prevalence of fungal diseases and increase in incidence of hospital-acquired fungal infection are the key factors driving the systemic aspergillosis and systemic candidiasis market.